n.a. (ARIA)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)
ARIAD To Webcast Conference Call On First Quarter 2015 Financial Results

ARIAD To Webcast Conference Call On First Quarter 2015 Financial Results

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its first quarter 2015 financial results on Thursday, May 7, 2015, before the market opens.

ARIAD Announces Issuance Of Key U.S. Patent On Brigatinib

ARIAD Announces Issuance Of Key U.S. Patent On Brigatinib

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the issuance of its first U.

ARIAD Announces Results Of Preclinical Studies On Brigatinib At The American Association For Cancer Research Annual Meeting

ARIAD Announces Results Of Preclinical Studies On Brigatinib At The American Association For Cancer Research Annual Meeting

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the results of a series of preclinical studies on its investigational tyrosine kinase inhibitor (TKI), brigatinib (AP26113) at the American Association for...

ARIAD Presents Updated Clinical Data On Brigatinib In Patients With ALK+ Non-Small Cell Lung Cancer

ARIAD Presents Updated Clinical Data On Brigatinib In Patients With ALK+ Non-Small Cell Lung Cancer

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced updated clinical data on its investigational tyrosine kinase inhibitor, brigatinib (AP26113), in patients with anaplastic lymphoma kinase positive (ALK+)...

Biotech Stock Mailbag: Bluebird's Sickle Cell Data, Ariad's Faux Suitors, XBiotech Blech

Biotech Stock Mailbag: Bluebird's Sickle Cell Data, Ariad's Faux Suitors, XBiotech Blech

Biotech columnist Adam Feuerstein answers readers' questions about health care.

ARIAD Announces Approval Of Iclusig (as Ponatinib Hydrochloride) In Canada

ARIAD Announces Approval Of Iclusig (as Ponatinib Hydrochloride) In Canada

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), today announced that Health Canada has approved the use of Iclusig™ (as ponatinib hydrochloride) in Canada for the treatment of adult patients with all phases of chronic...

ARIA: Insiders vs. Shorts

ARIA: Insiders vs. Shorts

The most recent short interest data was recently released by the NASDAQ for the 03/13/2015 settlement date, and ARIAD Pharmaceuticals, Inc. is one of the most shorted stocks of the Russell 3000, based on 8.44 "days to cover" versus the median component at 5.35.

Big Selloff on Wall Street as Stocks Plummet on Fed Jitters

Big Selloff on Wall Street as Stocks Plummet on Fed Jitters

Wednesday was a kick-you-in-the-guts kind of day.

Stocks Sell Off on Fed Jitters; Oil Rallies as Yemen Fights Intensify

Stocks Sell Off on Fed Jitters; Oil Rallies as Yemen Fights Intensify

Stocks are lower in a volatile trading session on Wednesday.

ARIAD Announces Dismissal Of Shareholder Class Action Lawsuit In Federal District Court

ARIAD Announces Dismissal Of Shareholder Class Action Lawsuit In Federal District Court

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the United States District Court for the District of Massachusetts dismissed the shareholder class action lawsuit filed in late 2013 against the Company and...

ARIAD And Medison Pharma Announce Approval Of Iclusig (Ponatinib) In Israel

ARIAD And Medison Pharma Announce Approval Of Iclusig (Ponatinib) In Israel

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Medison Pharma Ltd, Israel's leading international marketing group for innovative pharmaceuticals, today announced that the Israeli Ministry of Health has granted...

ARIAD Announces Presentations Of Preclinical Data At American Association For Cancer Research Annual Meeting

ARIAD Announces Presentations Of Preclinical Data At American Association For Cancer Research Annual Meeting

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced its schedule of preclinical data presentations to be made at the American Association for Cancer Research (AACR) Annual Meeting 2015, taking place Saturday,...

Insiders Were Right: ARIA Makes New 52-Week High

Insiders Were Right: ARIA Makes New 52-Week High

In trading on Monday, shares of ARIAD Pharmaceuticals, Inc. touched a new 52-week high of $8.74/share.

Cutting Through the Bull Shift

Bearish sentiment is rising, but has it reached a crescendo?

ARIAD Announces Dismissal Of Shareholder Derivative Lawsuit In Federal District Court

ARIAD Announces Dismissal Of Shareholder Derivative Lawsuit In Federal District Court

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) announced today that the United States District Court for the District of Massachusetts dismissed the shareholder derivative lawsuit filed in late 2013 against the Company and...

Nasdaq Strength Offsets Any Worries

Market players are unlikely to retreat until we push through 5,000.

Nasdaq's Winning Streak Nixed

Otherwise, market sticks to its recent pattern.

ARIAD To Present At The Cowen And Company 35th Annual Health Care Conference

ARIAD To Present At The Cowen And Company 35th Annual Health Care Conference

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Cowen and Company 35 th Annual Health Care Conference being held in Boston.

This Greece Charade Isn't Ending

But we can enjoy another dozen Greece-is-saved rallies.

ARIAD Confirms Receipt Of Sarissa Capital Management's Nomination Of Director Candidates

ARIAD Confirms Receipt Of Sarissa Capital Management's Nomination Of Director Candidates

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today confirmed that it has received notice of nomination by Sarissa Capital Management LP of two director candidates for election at the 2015 Annual Meeting.

Activist Hedge Fund Seeks Firing of Ariad Pharma CEO Berger

Activist Hedge Fund Seeks Firing of Ariad Pharma CEO Berger

Activist hedge fund Sarissa Capital is starting a proxy fight to force the ouster of Ariad Pharmaceuticals founder and CEO Harvey Berger.

ARIAD Reports 2014 Financial Results, Provides 2015 Financial Guidance And Outlines Strategic Objectives

ARIAD Reports 2014 Financial Results, Provides 2015 Financial Guidance And Outlines Strategic Objectives

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the fourth quarter and full year ended December 31, 2014 and issued 2015 financial guidance.

'Fast Money' Recap: Should You Buy European or U.S. Stocks?

'Fast Money' Recap: Should You Buy European or U.S. Stocks?

The trading panel discussed whether European stocks are better than U.S. stocks and whether you should buy or sell Alibaba.

ARIAD To Present At The RBC Capital Markets' Healthcare Conference

ARIAD To Present At The RBC Capital Markets' Healthcare Conference

ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced that it will present at the RBC Capital Markets' Healthcare Conference being held in New York City.

ARIAD To Present At The Leerink Global Healthcare Conference

ARIAD To Present At The Leerink Global Healthcare Conference

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Leerink Global Healthcare Conference being held in New York City.

ARIAD To Webcast Conference Call On Fourth Quarter And Year-End 2014 Financial Results

ARIAD To Webcast Conference Call On Fourth Quarter And Year-End 2014 Financial Results

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its fourth quarter and year-end 2014 financial results and issue 2015 financial guidance on Thursday, February 19, 2015, before the...

ARIAD Pharmaceuticals (ARIA) Flagged As Strong On High Volume

ARIAD Pharmaceuticals (ARIA) Flagged As Strong On High Volume

Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a strong on high relative volume candidate

Thomas J. DesRosier, Esq. Joins ARIAD As Executive Vice President, Chief Legal And Administration Officer, And Secretary. (Photo: Business Wire)

Thomas J. DesRosier, Esq. Joins ARIAD As Executive Vice President, Chief Legal And Administration Officer, And Secretary. (Photo: Business Wire)

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the appointment of Thomas J.

ARIAD Announces Final Decision From European Commission Endorsing Iclusig's Approved Indications Throughout Europe

ARIAD Announces Final Decision From European Commission Endorsing Iclusig's Approved Indications Throughout Europe

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the European Commission (EC) has endorsed the final opinion adopted by the Committee for Medicinal Products for Human Use (CHMP) on Iclusig ®...

ARIAD Announces Key Strategic Objectives For 2015 Expected To Lead Company To Profitability In Three Years

ARIAD Announces Key Strategic Objectives For 2015 Expected To Lead Company To Profitability In Three Years

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced its key strategic objectives for 2015, details of which will be presented at the 33 rd Annual J.